FGFR3 KO cell line available to order. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control provided. Knockout achieved by CRISPR/Cas9 X = 1 bp insertion Frameshift = 99.28%.
Images
Key facts
- Cell type
- HEK-293
- Species or organism
- Human
- Tissue
- Kidney
- Form
- Liquid
- Knockout validation
- Next Generation Sequencing, Western blot
- Mutation description
- Knockout achieved by CRISPR/Cas9 X = 1 bp insertion Frameshift = 99.28%
Alternative names
ACH, CD 333, CD333 antigen, CEK 2, FGFR3_HUMAN, Fibroblast growth factor receptor 3, Fibroblast growth factor receptor 3 (achondroplasia thanatophoric dwarfism), HSFGFR3EX, JTK 4, MFR 3, SAM 3, Tyrosine kinase JTK 4, Z FGFR 3, heparin-binding growth factor receptor, hydroxyaryl-protein kinase
Recommended products
FGFR3 KO cell line available to order. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control provided. Knockout achieved by CRISPR/Cas9 X = 1 bp insertion Frameshift = 99.28%.
Key facts
- Cell type
- HEK-293
- Species or organism
- Human
- Tissue
- Kidney
- Form
- Liquid
- Knockout validation
- Next Generation Sequencing, Western blot
- Mutation description
- Knockout achieved by CRISPR/Cas9 X = 1 bp insertion Frameshift = 99.28%
- Concentration
Properties
- Gene name
- FGFR3
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Next Generation Sequencing, Western blot
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 2 US: 2
- Adherent/suspension
- Adherent
- Gender
- Female
Handling procedures
- Initial handling guidelines
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.- Subculture guidelines
- All seeding densities should be based on cell counts gained by established methods.
- A guide seeding density of 2x104 cells/cm2 is recommended.
- Cells should be passaged when they have achieved 80-90% confluence.
- Culture medium
- DMEM (High Glucose) + 10% FBS
- Cryopreservation medium
- Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.
Storage
- Shipped at conditions
- Dry Ice
- Appropriate short-term storage conditions
- -196°C
- Appropriate long-term storage conditions
- -196°C
Notes
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
FGFR3 or fibroblast growth factor receptor 3 is a tyrosine kinase receptor with a molecular mass of approximately 95 kDa. This receptor also known as CD333 primarily interacts with fibroblast growth factors. It resides on the cell surface and is predominately expressed in bone cartilage and the brain. FGFR3 plays a major role in cell growth regulation and differentiation affecting how cells respond to external signals.
- Biological function summary
FGFR3 participates in important processes such as chondrogenesis and osteogenesis which are essential for bone growth and development. The receptor operates within a complex system involving interactions with ligand-induced dimerization and autophosphorylation. This phosphorylation event activates the receptor's intrinsic kinase activity further triggering downstream signaling pathways for cellular responses.
- Pathways
FGFR3 is involved with the MAPK/ERK and PI3K/AKT pathways which play significant roles in cell proliferation differentiation and survival. FGFR3 links closely with FGF ligands and similar receptor types such as FGFR1 and FGFR2 within these pathways. Differences in pathway activation can lead to diverse biological responses illustrating its pivotal role in maintaining cellular homeostasis.
- Associated diseases and disorders
FGFR3 mutations have significant links to skeletal disorders most notably achondroplasia characterized by short limbs and abnormal bone growth. FGFR3 also associates with bladder cancer where overactivity of the receptor leads to increased cell proliferation and survival. Mutations in FGFR3 often correlate with these conditions impacting signaling pathways and interacting with proteins such as PTPN11 highlighting its critical role in pathogenesis.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
3 product images
Western blot - Human FGFR3 knockout HEK-293 cell line (ab259775)
Lanes 1 - 3: Merged signal (red and green). Green - Anti-FGFR3 antibody [EPR2304(3)] ab133644 observed at 125kDa. Red - loading control Anti-GAPDH antibody [mAbcam 9484] - Loading Control ab9484 observed at 37 kDa.Anti-FGFR3 antibody [EPR2304(3)] ab133644 was shown to recognize in wild-type HEK-293 cells as signal was lost at the expected MW in FGFR3 knockout cells. Additional cross-reactive bands were observed in the wild-type and knockout cells. Wild-type and FGFR3 knockout samples were subjected to SDS-PAGE. Anti-FGFR3 antibody [EPR2304(3)] ab133644 and Anti-GAPDH antibody [mAbcam 9484] - Loading Control ab9484 (Mouse anti-GAPDH loading control) were incubated overnight at 4°C at 1/1000 dilution and 1/20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776 secondary antibodies at 1/20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-FGFR3 antibody [EPR2304(3)] (Anti-FGFR3 antibody [EPR2304(3)] ab133644) at 1/1000 dilution
Lane 1: Wild-type HEK-293 (Human epithelial cell line from embryonic kidney) whole cell lysate at 20 µg
Lane 2: FGFR3 knockout HEK-293 (Human epithelial cell line from embryonic kidney) whole cell lysate at 20 µg
Lane 2: Western blot - Human FGFR3 knockout HEK-293 cell line (ab259775)
Lane 3: Hep G2 (Human liver hepatocellular carcinoma cell line) whole cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 76 kDa, 88 kDa
Observed band size: 125 kDa
Next Generation Sequencing - Human FGFR3 knockout HEK-293 cell line (ab259775)
Knockout achieved by CRISPR/Cas9; X = 1 bp insertion; Frameshift = 99.28%
Next Generation Sequencing - Human FGFR3 knockout HEK-293 cell line (ab259775)
1 bp deletion after Gly51 of the WT protein
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com